132089-39-5 Usage
General Description
2-(4-trifluoromethyl-phenyl)-thiazole-4-carboxylic acid ethyl ester is a synthetic chemical compound that belongs to the class of thiazole compounds. It is commonly used in the field of biochemistry and pharmaceutical research as a building block to create new drugs and pharmaceuticals. The trifluoromethyl group on the phenyl ring makes the compound particularly useful for drug design, as it can enhance the chemical and physical properties of the resulting compounds. Additionally, the ethyl ester functional group allows for easy manipulation and derivatization of the compound, making it a versatile intermediate for the synthesis of various pharmaceuticals and biologically active substances. Overall, 2-(4-trifluoromethyl-phenyl)-thiazole-4-carboxylic acid ethyl ester is an important chemical in drug discovery and development.
Check Digit Verification of cas no
The CAS Registry Mumber 132089-39-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,2,0,8 and 9 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 132089-39:
(8*1)+(7*3)+(6*2)+(5*0)+(4*8)+(3*9)+(2*3)+(1*9)=115
115 % 10 = 5
So 132089-39-5 is a valid CAS Registry Number.
InChI:InChI=1/C13H10F3NO2S/c1-2-19-12(18)10-7-20-11(17-10)8-3-5-9(6-4-8)13(14,15)16/h3-7H,2H2,1H3
132089-39-5Relevant articles and documents
HETEROCYCLIC DERIVATIVE AND USE THEREOF
-
Page/Page column 161-162, (2011/01/11)
The present invention aims to provide a compound having superior pharmacological action, physicochemical properties and the like and useful as an sGC activation drug, or an agent for the prophylaxis and/or treatment of diseases such as hypertension, ischemic cardiac disease, cardiac failure, kidney disease, arteriosclerotic disease, atrial fibrillation, pulmonary hypertension, diabetes, diabetic complications, metabolic syndrome, peripheral arterial obstruction, erectile dysfunction and the like. An sGC activation drug containing a compound represented by the formula (II): wherein each symbol is as defined in the specification, or a salt thereof, as an active ingredient.
